Biogen (BIIB) Debt/Equity Ratio: History & Chart

Biogen Inc.(BIIB)

Drug Manufacturers - General · Cambridge, MA

$216.17-1.19 (-0.55%)

Delayed quote: Sep 15, 2026, 4:00 PM EDT

About Biogen Inc.

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

7,500 employees

www.biogen.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher A. Viehbacher

View full financials

BIIB Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.44

DEBT TO EQUITY RATIO AVG TTM

0.38

DEBT TO EQUITY RATIO AVG 3Y

0.42

DEBT TO EQUITY RATIO AVG 5Y

0.50

DEBT TO EQUITY RATIO AVG 10Y

0.52

DEBT TO EQUITY RATIO AVG 15Y

0.41

DEBT TO EQUITY RATIO AVG 20Y

0.35

CURRENT VS TTM AVG

+15.95%

CURRENT VS 3Y AVG

+5.46%

CURRENT VS 5Y AVG

-10.54%

CURRENT VS 10Y AVG

-14.33%

CURRENT VS 15Y AVG

+7.81%

CURRENT VS 20Y AVG

+28.11%

SECTOR MEDIAN · HEALTHCARE

0.69

median of 84 covered companies

CURRENT VS SECTOR MEDIAN

-35.29%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Biogen Inc. (BIIB)	$31.94B	0.44	0.38	0.42	0.50
Alnylam Pharmaceuticals, Inc. (ALNY)vs ›	$31.88B	0.94	10.47	10.47	5.79
DexCom, Inc. (DXCM)vs ›	$32.62B	0.53	0.87	1.00	1.01
Waters Corporation (WAT)vs ›	$31.19B	0.35	0.76	1.73	2.93
Alcon Inc. (ALC)vs ›	$33.05B	0.25	0.24	0.25	0.24
Zoetis Inc. (ZTS)vs ›	$30.78B	2.93	2.13	1.86	1.81
ResMed Inc. (RMD)vs ›	$33.28B	0.13	0.14	0.21	0.23
Centene Corp. (CNC)vs ›	$33.41B	0.71	0.84	0.83	0.81
GE HealthCare Technologies Inc. (GEHC)vs ›	$28.94B	0.92	1.04	1.09	0.74
Quest Diagnostics Incorporated (DGX)vs ›	$27.29B	0.85	1.00	0.92	0.85

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Biogen Inc. (BIIB)

$31.94B

0.44

0.38

0.42

0.50

Alnylam Pharmaceuticals, Inc. (ALNY)vs ›

$31.88B

0.94

10.47

5.79

DexCom, Inc. (DXCM)vs ›

$32.62B

0.53

0.87

1.00

1.01

Waters Corporation (WAT)vs ›

$31.19B

0.35

0.76

1.73

2.93

Alcon Inc. (ALC)vs ›

$33.05B

0.25

0.24

0.25

0.24

Zoetis Inc. (ZTS)vs ›

$30.78B

2.93

2.13

1.86

1.81

ResMed Inc. (RMD)vs ›

$33.28B

0.13

0.14

0.21

0.23

Centene Corp. (CNC)vs ›

$33.41B

0.71

0.84

0.83

0.81

GE HealthCare Technologies Inc. (GEHC)vs ›

$28.94B

0.92

1.04

1.09

0.74

Quest Diagnostics Incorporated (DGX)vs ›

$27.29B

0.85

1.00

0.92

0.85

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Biogen Inc. (BIIB)?

The debt to equity ratio for BIIB stock is 0.44.

Is Biogen Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 0.44 is 11% below its 5-year average of 0.50, near the low end of its 5-year range (0.35–0.73).

What is the TTM average debt to equity ratio for Biogen Inc. (BIIB)?

The TTM average debt to equity ratio for BIIB stock is 0.38.

What is the 3Y average debt to equity ratio for Biogen Inc. (BIIB)?

The 3Y average debt to equity ratio for BIIB stock is 0.42.

What is the 5Y average debt to equity ratio for Biogen Inc. (BIIB)?

The 5Y average debt to equity ratio for BIIB stock is 0.50.

What is the 10Y average debt to equity ratio for Biogen Inc. (BIIB)?

The 10Y average debt to equity ratio for BIIB stock is 0.52.

What is the 15Y average debt to equity ratio for Biogen Inc. (BIIB)?

The 15Y average debt to equity ratio for BIIB stock is 0.41.

What is the 20Y average debt to equity ratio for Biogen Inc. (BIIB)?

The 20Y average debt to equity ratio for BIIB stock is 0.35.

DATE	DEBT TO EQUITY RATIO
2026-06-30	0.44
2026-03-31	0.35
2025-12-31	0.38
2025-09-30	0.36
2025-06-30	0.37
2025-03-31	0.39
2024-12-31	0.40
2024-09-30	0.41
2024-06-30	0.42
2024-03-31	0.46
2023-12-31	0.50
2023-09-30	0.53
2023-06-30	0.46
2023-03-31	0.48
2022-12-31	0.49
2022-09-30	0.52
2022-06-30	0.64
2022-03-31	0.67
2021-12-31	0.70
2021-09-30	0.73
2021-06-30	0.71
2021-03-31	0.72
2020-12-31	0.73
2020-09-30	0.73
2020-06-30	0.69
2020-03-31	0.51
2019-12-31	0.48
2019-09-30	0.45
2019-06-30	0.49
2019-03-31	0.46
2018-12-31	0.46
2018-09-30	0.43
2018-06-30	0.48
2018-03-31	0.42
2017-12-31	0.47
2017-09-30	0.51
2017-06-30	0.56
2017-03-31	0.57
2016-12-31	0.54
2016-09-30	0.54
2016-06-30	0.57
2016-03-31	0.63
2015-12-31	0.70
2015-09-30	0.62
2015-06-30	0.05
2015-03-31	0.05
2014-12-31	0.05
2014-09-30	0.06
2014-06-30	0.06
2014-03-31	0.07
2013-12-31	0.07
2013-09-30	0.09
2013-06-30	0.09
2013-03-31	0.12
2012-12-31	0.16
2012-09-30	0.17
2012-06-30	0.17
2012-03-31	0.17
2011-12-31	0.17
2011-09-30	0.17
2011-06-30	0.20
2011-03-31	0.21
2010-12-31	0.22
2010-09-30	0.21
2010-06-30	0.00
2010-03-31	0.19
2009-12-31	0.18
2009-09-30	0.17
2009-06-30	0.18
2009-03-31	0.19
2008-12-31	0.19
2008-09-30	0.18
2008-06-30	0.19
2008-03-31	0.19
2007-12-31	0.28
2007-09-30	0.31
2007-06-30	0.01
2007-03-31	0.01
2006-12-31	0.01
2006-09-30	0.01
2006-06-30	0.01
2006-03-31	0.01
2005-12-31	0.01
2005-09-30	0.01
2005-06-30	0.01
2005-03-31	0.12
2004-12-31	0.12
2004-09-30	0.13
2004-06-30	0.12
2004-03-31	0.12
2003-12-31	0.13
2003-09-30	0.02
2003-06-30	0.02
2003-03-31	0.05
2002-12-31	0.03
2002-09-30	0.05

DATE

DEBT TO EQUITY RATIO

2026-06-30

0.44

2026-03-31

0.35

2025-12-31

0.38

2025-09-30

0.36

2025-06-30

0.37

2025-03-31

0.39

2024-12-31

0.40

2024-09-30

0.41

2024-06-30

0.42

2024-03-31

0.46

2023-12-31

0.50

2023-09-30

0.53

2023-06-30

0.46

2023-03-31

0.48

2022-12-31

0.49

2022-09-30

0.52

2022-06-30

0.64

2022-03-31

0.67

2021-12-31

0.70

2021-09-30

0.73

2021-06-30

0.71

2021-03-31

0.72

2020-12-31

0.73

2020-09-30

0.73

2020-06-30

0.69

2020-03-31

0.51

2019-12-31

0.48

2019-09-30

0.45

2019-06-30

0.49

2019-03-31

0.46

2018-12-31

0.46

2018-09-30

0.43

2018-06-30

0.48

2018-03-31

0.42

2017-12-31

0.47

2017-09-30

0.51

2017-06-30

0.56

2017-03-31

0.57

2016-12-31

0.54

2016-09-30

0.54

2016-06-30

0.57

2016-03-31

0.63

2015-12-31

0.70

2015-09-30

0.62

2015-06-30

0.05

2015-03-31

0.05

2014-12-31

0.05

2014-09-30

0.06

2014-06-30

0.06

2014-03-31

0.07

2013-12-31

0.07

2013-09-30

0.09

2013-06-30

0.09

2013-03-31

0.12

2012-12-31

0.16

2012-09-30

0.17

2012-06-30

0.17

2012-03-31

0.17

2011-12-31

0.17

2011-09-30

0.17

2011-06-30

0.20

2011-03-31

0.21

2010-12-31

0.22

2010-09-30

0.21

2010-06-30

0.00

2010-03-31

0.19

2009-12-31

0.18

2009-09-30

0.17

2009-06-30

0.18

2009-03-31

0.19

2008-12-31

0.19

2008-09-30

0.18

2008-06-30

0.19

2008-03-31

0.19

2007-12-31

0.28

2007-09-30

0.31

2007-06-30

0.01

2007-03-31

0.01

2006-12-31

0.01

2006-09-30

0.01

2006-06-30

0.01

2006-03-31

0.01

2005-12-31

0.01

2005-09-30

0.01

2005-06-30

0.01

2005-03-31

0.12

2004-12-31

0.12

2004-09-30

0.13

2004-06-30

0.12

2004-03-31

0.12

2003-12-31

0.13

2003-09-30

0.02

2003-06-30

0.02

2003-03-31

0.05

2002-12-31

0.03

2002-09-30

0.05

Debt to Equity Ratio: 0.44

BIIB Debt to Equity Ratio

BIIB Average Debt to Equity Ratio Chart

BIIB Current vs Average Debt to Equity Ratio Chart

BIIB Debt to Equity Ratio Metrics

BIIB Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

BIIB Debt to Equity Ratio History

Related Metrics